ASAM/Ohio Waiver Training: Kettering, Ohio, September 29-30, 2020

Product not yet rated

  • Register
    • Non-Member - Free!
    • Regular Member - Free!
    • Retired - Free!
    • Early Career Physician - Free!
    • Resident - Free!
    • Student - Free!
    • Associate - Free!
    • ASAM Staff - Free!
    • International Member - Free!
    • Emeritus Member - Free!
    • Provisional Member - Free!
    • Fellow Member - Free!
    • Honorary Member - Free!
    • CRT Member - Free!

   image       image    

 image

ASAM/Ohio Waiver Training

 Day 1: 8-Hour ASAM Treatment of Opioid Use Disorder Course

Tuesday, September 29, 2020 

8:30 am - 5:30 pm

Click here to access Zoom Webinar

DAY 2: 4-Hour OhioMHAS Implementation Training

Wednesday, September 30, 2020

8:30 am - 12:30 pm

Click here to access Zoom Webinar

This course is offered in partnership with the Ohio Department of Mental Health and Addiction Services (OhioMHAS) and Substance Abuse and Mental Health Service Administration (SAMHSA). The curriculum for this course has been specifically designed for Ohio licensed physicians, nurse practitioners, and physician assistants.

Welcome to the Ohio DEA DATA 2000 One and a Half Day Waiver Training. Please LOG IN or Create a New Account to register for the course. If you do not know your password, or you have forgotten it, select "Forgot Password" and you will be emailed a link to reset your password.

The 8-hour section of the training provided by the American Society of Addiction Medicine (ASAM) covers all medications and treatments for opioid use disorder, and provides the required education needed to obtain the waiver to prescribe buprenorphine. ASAM is an approved provider by CSAT/SAMHSA of DATA 2000 training. This course is SAMHSA-supported. 

The 4-hour section of the training provided by OhioMHAS includes training from experts around Ohio that will enhance the prescriber’s knowledge about opioid prescribing and buprenorphine policies (e.g., low-dose prescribing according to federal and state guidelines and DEA guidance on documentation). 

 Once you have completed the entire day and a half training, return to the ASAM e-Learning Center and complete the necessary steps listed in the "content" tab to obtain CME and apply for your waiver. If you have any questions, please contact education@ASAM.org


Overview of Legislation

Physicians

The Drug Abuse Treatment Act of 2000 (DATA 2000) specifies training is necessary for physicians to obtain a waiver to engage in office‐based treatment of opioid use disorders using drugs approved by the FDA on Schedules III, IV, and V. This course addresses those requirements using a curriculum approved by CSAT/SAMHSA and ASAM, who is one of the national organizations named in the DATA 2000 legislation as eligible to prepare and administer these courses.

Nurse Practitioners & Physician Assistants

On July 22, 2016, President Obama signed the Comprehensive Addiction and Recovery Act (CARA) into law. CARA authorizes qualified NPs and PAs to become waivered to prescribe buprenorphine in office-based settings for patients with Opioid Use Disorder (OUD) for a five-year period expiring in October 2021.    

To qualify, NPs and PAs must: 

  • Be licensed under state law to prescribe schedule III, IV, or V medications for pain  
  • Complete not less than 24 hours of appropriate education through a qualified provider
  • Through other training or experience, demonstrate the ability to treat and manage OUD  
  • If required by state law, be supervised or work in collaboration with a qualifying physician to prescribe medications for the treatment of OUD

ASAM, AAPA and AANP have formed a collaborative to provide the 24-hour waiver training for physician assistants and nurse practitioners. The three organizations are authorized by statute to provide this training. Educational content has been identified and/or created to satisfy the 24-hour requirement as described in the Comprehensive Addiction and Recovery Act (CARA).

Please ensure that your state regulations allow you to prescribe buprenorphine and other medications to treat Opioid Use Disorder before you apply for the waiver. Some states may have overriding state legislation that will prevent NPs/PAs from prescribing these medications even if Federal law allows it. Click here to learn more about applying for the waiver.

This training is divided into two parts of 8 hours and 16 hours. This 8 hour course will satisfy Part 1 and Part 2 can be completed online for free.

For NPs (CE Credit through AANP): Click Here   

For PAs (AAPA Category 1 CME Credit): Click Here

Funding for this conference was made possible (in part) by the Ohio Opioid STR Project- 1H79TI080261-01 grant from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

At the conclusion of this activity, learners should be able to:

  1. Apply for a waiver to prescribe buprenorphine to their patients with opioid use disorders
  2. Identify and assess patients who are appropriate for treatment with medications
  3. Have specific knowledge concerning the use of medications to manage patients with addiction involving opioid use
  4. Discuss the psychiatric and medical co-morbidities associated with opioid addiction

Key:

Complete
Failed
Available
Locked
Treatment of Opioid Use Disorder: Waiver Qualifying - Kettering, Ohio: Tuesday, September 29, 2020
09/29/2020 at 8:30 AM (EDT)   |  600 minutes
09/29/2020 at 8:30 AM (EDT)   |  600 minutes
Live Implementation Half-Day Training - Ohio: Wednesday, September 30, 2020
09/30/2020 at 8:30 AM (EDT)   |  300 minutes
09/30/2020 at 8:30 AM (EDT)   |  300 minutes
CME Evaluation
17 Questions
17 Questions Please complete the evaluation to claim CME.
Download CME Certificate
Up to 8.00 medical credits available  |  Certificate available
Up to 8.00 medical credits available  |  Certificate available 8 Credits
Send your CME Certificate to SAMHSA
Apply For Your Waiver
Select the "Apply For Your Waiver" button to begin.
Select the "Apply For Your Waiver" button to begin. Providers, please follow this link to apply for your waiver:
Need Help?
Contact Us
Contact Us If you need help or have questions about this process ​please email education@asam.org ​or call 301.656.3920 and ask to speak with an education team member​.
ACCME Accredited with Commendation

CME/CE Credits

ACCME Accreditation Statement

The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

AMA Credit Designation Statement

The American Society of Addiction Medicine designates this live internet-based activity for a maximum of 8 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

NAADAC, the Association for Addiction Professionals

This activity has been approved by the American Society of Addiction Medicine, as a NAADAC Approved Education Provider, for educational credits. NAADAC Provider #295, ASAM is responsible for all aspects of the programming.

California Association for Drug/Alcohol Educators (CAADE)

This educational program is approved by CAADE: #CP40 999 1222

California Association of DUI Treatment Centers (CADTP)

This educational program is approved by CADTP: #205

Continuing Education Credits (CEUs)

Non-physician participants will receive a certificate of attendance upon completion of the activity and an online evaluation confirming their participation. Participants should submit his/her certificate of attendance to their professional organization/institute.

Maintenance of Certification (MOC)

ABPM Maintenance of Certification (MOC)

The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 8 LLSA credit towards ABPM MOC Part II requirements.

ABA Maintenance of Certification (MOC)

This activity contributes to the CME component of the American Board of Anesthesiology’s redesigned Maintenance of Certification in Anesthesiology TM (MOCA®) program, known as MOCA 2.0®.

ABP Maintenance of Certification (MOC)

Successful completion of this CME activity, which includes participation in the activity, with individual assessments of the participant and feedback to the participant, enables the participant to earn a maximum of 8 MOC points in the American Board of Pediatrics’ (ABP) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABP MOC credit.

 ABIM Maintenance of Certification (MOC)

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 8 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

ABAM Transitional Maintenance of Certification (Tmoc)

Successful completion of this activity can be used to satisfy the American Board of Addiction Medicine (ABAM) for Tmoc as credits towards ABAM LLSA Part II requirements.

American Board of Psychiatry and Neurology (ABPN)

Successful completion of this CME activity can be used to satisfy the American Board of Psychiatry and Neurology’s (ABPN) CME requirement for Maintenance of Certification program.

Program Planning Committee, CME Committee, Medical Education Council (MEC), and Faculty Disclosure Information

In accordance with disclosure policies of ASAM and the ACCME, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all CME activities. These policies include resolving all possible conflicts of interest for the Planning Committees, CME Committee, MEC, and Faculty. All activity Planning Committee members and Faculty have disclosed relevant financial relationship information. The ASAM CME Committee has reviewed these disclosures and determined that the relationships are not inappropriate in the context of their respective presentations and are not inconsistent with the educational goals and integrity of the activity.

ASAM Treatment of Opioid Use Disorder Course Program Planning Committee

NameNature of Relevant Financial Relationship
Dan Alford, MD, MPH, DFASAM, ChairNone
Edwin Salsitz, MD, DFASAM, Curriculum DirectorNone
Alta DeRoo, MD, FASAM, FACOGNone
Soraya Azari, MDNone
Jill Mattingly, DHSc, MMSc, PA-CNone
Debra Newman, PA-C, MPAS, MPHCommercial Interest: AbbVie
What was received: Honoraria
Role: Expert faculty for CME activities
Commercial Interest: Gilead
What was received: Honoraria
Role: Expert faculty for CME activities
Mary McMasters, MD, DFASAMNone
Yngvild K. Olsen, MD, MPH, DFASAMNone
Shawn Ryan, MD, MBA, FASAMCommercial Interest: Crosswave 
What was received: Stock 
Role: Advisor
Commercial Interest: Dynamicare
What was received: Stock
Role: Advisor
Kristin Smith, DNP, FNP-C, AAHIVSNone
Tricia E. Wright, MD, MS, FACOG, DFASAMNone

ASAM CME Committee

NameNature of Relevant Financial Relationship
Catherine Friedman, MD, FAPA, DFASAM, ChairNone
Catharina Armstrong, MD, MPHNone
Subhadeep Barman, MD, FASAM, FAPANone
Benjamin Bearnot, MD, MPH, FASAMCommercial Interest: Johnson and Johnson
What was received: Common stock
Role: None
Commercial Interest: Baxter International
What was received: Common stock
Role: None
Commercial Interest: Takeda Pharmaceuticals
What was received: Common stock
Role: none
R. Jeffrey Goldsmith, MD, DLFAPA, DFASAMCommercial Interest: Alkermes
What was received: Travel expenses
Role: Speaker
Zwaantje H. Hamming, FNP-C, CARN-APNone
Herbert L. Malinoff, MD, FACP, DFASAM None
Noel Ilogu, MD, MRCP, DFASAMNone
Edwin A. Salsitz, MD, DFASAMNone
 ASAM Staff and Consultants
Arlene C. Deverman, MA, CAE, CFRENone
Sandy MetcalfeNone
Kate M. BrundageNone

ASAM Medical Education Council

NameNature of Relevant Financial Relationship
Peter Selby, MBBS, CCFP, FCFP, MHSc, DFASAM, ChairCommercial Interest: Johnson & Johnson; Novartis; Pfizer Inc.
What was received: Received free/discounted materials for research studies through an open tender process
Role: Research Studies
Commercial Interest: Pfizer Inc. Global Research Awards for Nicotine Dependence (GRAND).
What was received: Grant funds
Role: Principal investigator on research study
Commercial Interest: Johnson & Johnson E-NRT Advisory Board
What was received: Consulting Fees
Role: Consulting on Johnson & Johnson E-NRT Advisory Board
Daniel P. Alford, MD, MPH, DFASAMNone
Michael Fingerhood, MD, FACP, FASAMNone
Catherine R. Friedman, MD, FAPA, DFASAMNone
Adam J. Gordon, MD, MPH, FACP, DFASAMNone
Miriam S. Komaromy, MD, FACP, DFASAMNone
Edwin A. Salsitz, MD, DFASAMNone
Brian Hurley, MD, MBA, DFASAMNone
Mark A. Weiner, MD, FASAMNone
 ASAM Staff and ConsultantsNone
Penny S. Mills, MBANone
Arlene C. Deverman, MA, CAE, CFRENone
Marcia Jackson, PhDNone
Dawn C. PiotrowskiNone
Molly S. MazukNone
Alexandra (Alli) KrouseNone
Jennifer L. ButchartCommercial Interest: Merck
What was received: Spouse received stocks
Role: Stockholder


Apply

NPs and PAs who have completed the 24 hours of required training may seek to obtain a DATA 2000 waiver for up to 30 patients by completing the Waiver Notification Form. Effective February 27, 2017, SAMHSA will only accept electronic submissions of the NOI.

NPs and PAs may send copies of their training certificates to infobuprenorphine@samhsa.hhs.gov or fax them to 301.576.5237. These waiver applications are forwarded to the Drug Enforcement Administration (DEA), which will assign the NP or PA a special identification number. DEA regulations require this number to be included on all buprenorphine prescriptions for opioid dependency treatment, along with the NP’s or PA’s regular DEA registration number.

SAMHSA shall review waiver applications within 45 days of receipt. If approved, NPs and PAs will receive a letter via email that confirms their waiver and includes their prescribing identification number. 

Qualify

To qualify for a waiver to treat patients with Opioid Use Disorder, NPs and PAs must: 

  • Be licensed under state law to prescribe schedule III, IV, or V medications for pain  
  • Complete not less than 24 hours of appropriate education through a qualified provider
  • Through other training or experience, demonstrate the ability to treat and manage OUD  
  • If required by state law, be supervised or work in collaboration with a qualifying physician to prescribe medications for the treatment of OUD

Please ensure that your state regulations allow you to prescribe buprenorphine and other medications to treat OUD before you apply for the waiver.  Some states may have overriding state legislation that will prevent NPs from prescribing these medications even if Federal law allows it.

Funding for this training was made possible (in part) by the Ohio State Opiate Response (SOR) grant #3H79T1081684-01S1 from SAMHSA. The views expressed in written materials or publications do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

Funding for this initiative was made possible (in part) by grant no. 1H79TI026793-01 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

Licensed physicians, nurse practitioners, and physician assistants who wish to obtain a waiver to prescribe buprenorphine in office based treatment of opioid use disorders.